Health Care·Biotechnology·$2.1B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.77 | N/A | +48.87% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.77 | N/A | +48.87% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains focused on advancing their clinical programs. They emphasized the potential impact of their research on future revenue.
Management expressed optimism about ongoing projects and future developments.
They highlighted the importance of upcoming trials in their pipeline.
Sarepta Therapeutics reported a larger-than-expected loss per share, which was a positive surprise compared to analyst expectations. However, the lack of revenue data and no guidance update contributed to a slight decline in the stock price. Investors may be cautious as they await more information on the company's future performance and clinical trial outcomes.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SBA COMMUNICATIONS C Class A REIT
Feb 28, 2022